An inhaled RNA drug showed first signs of benefit in a rare cystic fibrosis mutation

An inhaled drug that works on RNA, the messenger copied from DNA before a protein is built, produced the first signs of clinical benefit in a small group of people with a rare form of cystic fibrosis — a proof-of-concept result the authors describe as a milestone for a whole class of therapy [s1]. The trial was tiny and exploratory, so the finding is a door opening rather than a treatment arriving.

Cystic fibrosis (CF) is caused by faults in the gene for CFTR, a channel that moves salt and water across cell surfaces; when it fails, thick mucus clogs the lungs and other organs. The transformative CF drugs of the past decade are "modulators" that fix the CFTR protein, but they only work for certain mutations. The 3849+10 kb C→T mutation is different: it creates a splicing error, so the cell inserts an extra stretch of genetic code — a "cryptic exon" carrying a premature stop signal — and builds a truncated, non-functional protein [s1]. SPL84 is an inhaled antisense oligonucleotide, a short synthetic strand of nucleic acid designed to mask that faulty splice site so the cell makes a working CFTR protein instead [s1].

What the trial did

The study was a phase 2a randomised, placebo-controlled, double-blind, multiple-ascending-dose trial in people with CF who carry the 3849+10 kb C→T mutation [s1]. Participants inhaled SPL84 at 25 mg or 50 mg, or a placebo, once a week for nine weeks [s1]. The main goals were the ordinary ones for an early trial — safety, tolerability, and how the drug moves through the body — with lung function and symptoms tracked as exploratory signals. Those exploratory measures were the percent-predicted forced expiratory volume in one second (ppFEV1, the standard gauge of how much air a person can blow out), a mid-flow measure called ppFEF25–75, and the respiratory symptom score from the Cystic Fibrosis Questionnaire–Revised [s1].

What it found

Seventeen people were included in the analysis and fifteen completed all treatments [s1]. SPL84 was well tolerated: there were no drug-related serious adverse events, and most side effects were mild or moderate and in keeping with the underlying disease [s1]. On the efficacy side, the trial reported improvements in lung function — defined as a rise from baseline in ppFEV1 of at least five points — in up to 70% of treated participants per dose cohort, alongside improvement in the other measures tracked [s1]. The authors present this as, to their knowledge, the first evidence of potential clinical benefit from a nucleic-acid therapy that targets RNA in a lung disease [s1].

How to read it

The importance of this trial is conceptual more than clinical. For people with the 3849+10 kb mutation, the dominant CFTR modulators are a poor fit because the problem is a splicing error, not a misshapen protein — so a therapy that corrects the splice directly would fill a genuine gap. That an inhaled antisense drug appears safe and shows a lung-function signal is a meaningful first step, and it hints at a template other RNA-targeted inhaled drugs might follow [s1]. A different nucleic-acid strategy for CF — a suppressor tRNA delivered in a lipid nanoparticle — has been explored in parallel, and we have covered that approach separately.

The cautions are large and the authors do not hide them. Seventeen participants is a very small sample, nine weeks is a brief exposure, and lung-function and symptom endpoints were exploratory — meaning the trial was not built or powered to prove they changed, only to look for a signal [s1]. "Improvement in up to 70%" describes a best-performing cohort, not an average effect, and an open, early trial like this cannot establish durability or rule out a placebo contribution on measures as variable as ppFEV1. None of that is a criticism of the design; it is what a phase 2a study is for.

What to watch

The questions now are whether larger, longer, adequately powered trials confirm a lung-function benefit, whether the effect holds across the dose range, and how the approach performs in the many other CF mutations — and other lung diseases — where a splice-correcting inhaled drug might in principle help. The broader prize, if the concept is borne out, is a route to treat genetic lung disease by editing the message rather than the gene.

This article describes early research and is not medical advice. Treatment decisions in cystic fibrosis belong with a specialist CF team.